{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"36.9","value":"0.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"33.7","value":"10.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"31.9","value":"0.0"}]}],"title":"mCR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"36.9","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"20.6","value":"0.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"31.9","value":"0.0"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"36.9","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"20.6","value":"0.0"},{"groupId":"OG002","lowerLimit":"9.3","upperLimit":"66.7","value":"33.3"}]}],"title":"SD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"58.4","value":"20.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"33.7","value":"10.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"31.9","value":"0.0"}]}],"title":"CRi"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"36.9","value":"0.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"33.7","value":"10.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"31.9","value":"0.0"}]}],"title":"Unconfirmed SD"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"36.9","value":"0.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"33.7","value":"10.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"31.9","value":"0.0"}]}],"title":"Unconfirmed CRi"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"36.9","value":"0.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"33.7","value":"10.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"31.9","value":"0.0"}]}],"title":"mCR (CRi not included)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.7","upperLimit":"88.8","value":"60.0"},{"groupId":"OG001","lowerLimit":"1.0","upperLimit":"33.7","value":"10.0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"31.9","value":"0.0"}]}],"title":"CRc"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"For all MDS participants, disease specific efficacy measures included: CRi (bone marrow showing \\<5% myeloblasts with platelets \\<100,000/mcL or neutrophils \\<1000/mcL, including confirmed and unconfirmed responses); PR (repeat bone marrow myeloblasts showing decreased by \\>= 50% decrease but still \\>5%, peripheral blood showing neutrophils \\>= 1,000/mcL, platelets \\>= 100,000/mcL and Hgb\\>=11g/dL; including confirmed and unconfirmed responses); SD (including confirmed and unconfirmed responses, failure to achieve PR and no evidence of progression for \\>8 weeks); marrow complete response (mCR) (bone marrow showing \\<=5% myeloblasts and decreased by \\>= 50%), partial cytogenetic response (\\>=50% reduction of chromosomal abnormality) and complete cytogenetic response (CRc) (disappearance of chromosomal abnormality with no appearance of now ones).","dispersionType":"80% Confidence Interval","groups":[{"description":"Participants received 1-2 cycles of induction (glasdegib and daunorubicin/cytarabine), followed by 2-4 cycles of consolidation (glasdegib and high dose cytarabine) and a maximum of 6 cycles of maintenance (glasdegib alone). Daunorubicin was given on Days 1-3 QD at a dose of 60 mg/m\\^2/day by IV together with cytarabine on Days 1-7 at a dose of 100 mg/m\\^2/day by continuous IV infusion for each cycle of induction. Cytarabine was given on Days 1, 3, and 5 at a dose of 1 g/m\\^2 administered as a 3-hour IV infusion every 12 hours (2 g/m\\^2/day) for each cycle of consolidation. Glasdegib tablets 100 mg QD was started on induction Cycle 1/Day -3 and administered continuously QD thereafter for the duration of the study. A cycle was defined as 28 days.","id":"OG000","title":"Phase 2 Fit: Glasdegib 100 mg + Cytarabine/Daunorubicin"},{"description":"Participants received oral doses of glasdegib tablets 100 mg QD in 28-day cycles on a continuous basis, starting on Day 1 of Cycle 1. LDAC was given at a dose of 20 mg subcutaneously BID on Days 1-10 of the 28 day cycles.","id":"OG001","title":"Phase 2 Unfit: Glasdegib 100 mg + LDAC"},{"description":"Participants received LDAC subcutaneously at a dose of 20 mg BID on Days 1-10 of the 28 day cycles.","id":"OG002","title":"Phase 2 Unfit: LDAC Alone"}],"paramType":"NUMBER","populationDescription":"MDS participants in the Full analysis set: all enrolled participants of Phase 2 Fit arm who received at least 1 dose of study medication, and all randomized participants of Phase 2 Unfit arm.","reportingStatus":"POSTED","timeFrame":"4 years","title":"Percentage of Participants With Disease-specific Efficacy for Myelodysplastic Syndrome (MDS) at Phase 2 Fit and Unfit","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}